Century Therapeutics (IPSC) Accumulated Depreciation & Amortization (2022 - 2025)
Century Therapeutics (IPSC) has disclosed Accumulated Depreciation & Amortization for 4 consecutive years, with $39.1 million as the latest value for Q1 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization changed N/A to $39.1 million in Q1 2025 year-over-year; TTM through Mar 2025 was $39.1 million, a N/A change, with the full-year FY2024 number at $36.1 million, up 57.89% from a year prior.
- Accumulated Depreciation & Amortization was $39.1 million for Q1 2025 at Century Therapeutics, up from $36.1 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $39.1 million in Q1 2025 to a low of $6.5 million in Q1 2022.
- A 4-year average of $22.2 million and a median of $21.2 million in 2023 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 143.07% in 2023, then soared 54.68% in 2024.
- Century Therapeutics' Accumulated Depreciation & Amortization stood at $13.7 million in 2022, then skyrocketed by 67.25% to $22.8 million in 2023, then soared by 57.89% to $36.1 million in 2024, then rose by 8.45% to $39.1 million in 2025.
- Per Business Quant, the three most recent readings for IPSC's Accumulated Depreciation & Amortization are $39.1 million (Q1 2025), $36.1 million (Q4 2024), and $32.7 million (Q3 2024).